For the construction of a new state of the art vaccine manufacturing facility, Sanofi is investing €350 million($433.18 million) at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario, Canada.
Demonstrating Sanofi’s commitment to innovation and leadership in global public health, the investment bolsters Sanofi’s Canada operations. The new investment is the largest ever investment by Sanofi in a single building and this will increase capacity to meet the demands for pediatric and booster vaccines globally.
According to David Loew, Executive Vice President and Head of Sanofi Pasteur:
“Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe. Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.”
The building that is expected to be completed in 2021 will allow Sanofi Pasteur to meet the growing demand of five-component acellular pertussis (5-acP) antigen. Upon its completion, the facility will be equipped to produce the antigens used in the diphtheria and tetanus vaccines.
Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi added the following:
“This project is one of the most important investments for the Sanofi global industrial network. It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.”
Founded in 1973 and headquartered in France, Sanofi is a global biopharmaceutical company focused on human health. Sanofi employs more than 100000 people across 100 countries and it operates in two main segments namely, Pharmaceuticals and Vaccines